Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
P/B ratio for Mirati Therapeutics, Inc. (MRTX)
P/B ratio as of 2022: 2.56
According to Mirati Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.56. At the end of 2021 the company had a P/B ratio of 5.45.
P/B ratio history for Mirati Therapeutics, Inc. from 2003 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 2.56 |
| 2021 | 5.45 |
| 2020 | 7.26 |
| 2019 | 12.63 |
| 2018 | 6.50 |
| 2017 | 3.22 |
| 2016 | 1.95 |
| 2015 | 4.52 |
| 2014 | 8.90 |
| 2013 | 7.10 |
| 2012 | 2.04 |
| 2011 | 1.65 |
| 2010 | 1.40 |
| 2009 | 0.44 |
| 2008 | 0.17 |
| 2007 | 0.11 |
| 2006 | 0.10 |
| 2005 | 0.13 |
| 2004 | 0.08 |
| 2003 | 0.09 |